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Patients with intragenic mutations of the VHL gene have a typical disease presentation. However in cases of large
VHL gene deletions which involve other genes in the proximity of the VHL gene a presentation of the disease can
be different.
To investigate whether large VHL deletions that remove the FANCD2 gene have an effect on the disease phenotype,
we studied a family with a 50 kb large deletion encompassing these two genes. Four patients in this family were
affected by VHL-related lesions. However one carrier of the deletion also had bilateral ductal breast cancer at age 46
and 49. Both tumors were of ~2 cm in diameter. On one side lymph nodes were affected. One tumor was ER- and
PR-negative (HER2 s unknown) and the second was ER- and PR-positive, and HER2-negative.
Our study suggests that a deletion of FANCD2 gene, an important gene in the DNA repair pathway, may be
associated with an increased risk of breast cancer, but further studies are needed in this regard.Introduction
Von Hippel-Lindau (VHL) disease is a rare autosomal
dominant disorder characterized by a predisposition
to haemangioblastomas of the central nervous system
(cHAB) and retina (rHAB), renal cell carcinomas (RCC),
pheochromocytomas and paragangliomas, endolymphatic
sac tumors (ELST), pancreatic neuroendocrine tumors
(PNET), papillary cystadenomas of epididymis, and adnexal
papillary tumors of probable mesonephric origin (APMO)
[1-3]. The disease is caused by germline mutations in the
VHL tumor suppressor gene on a short arm of chromo-
some 3. In most cases, VHL disease is caused by single
base substitutions, microdeletions or microinsertions, how-
ever approximately 30% of VHL patients carry a deletion
of a part or of the entire VHL gene [4-6].
Patients with small intragenic mutations of the VHL
gene have a typical disease presentation. However this may
not be the truth in cases of carriers of large deletions. Large
deletions may involve other genes in the proximity of the* Correspondence: krzystolikk@poczta.onet.pl
1Department of Ophthalmology, Pomeranian Medical University (PUM),
Szczecin, Poland
2International Hereditary Cancer Center, Department of Genetics, Pathology
PUM, Szczecin, Poland
Full list of author information is available at the end of the article
© 2014 Krzystolik et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.VHL gene, i.e. FANCD2, C3orf10, CNTN6, IRAK2, GHRL
or MLH1 genes that may have an effect on the disease
presentation. For example, there is some evidence to sug-
gest that large deletions of VHL and of C3orf10 are associ-
ated with lower life time risk of kidney cancer compared to
the deletions which do not include the C3orf10 gene
[7-10]. However, the impact of the extent of large deletions
encompassing VHL and other adjacent genes on pheno-
type has not been extensively studied. In particular, it was
not investigated whether large VHL deletions that include
the FANCD2 gene - an important gene in the DNA
damage repair signaling pathway, have an effect on disease
phenotype.Material and methods
Patients
We studied a phenotype of a family with a large deletion
of the VHL gene that involves the FANCD2 gene. This
family included 11 family members (Figure 1), 4 patients
had VHL-related tumors, and 2 patients had other tu-
mors (breast cancer, prostate cancer) (Table 1). Blood
samples were available from 3 family members (a 53 year
old woman with bilateral breast cancer and VHL disease,
her 31 year old son with VHL disease and her healthy
30 year old daughter).al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Pedegree of the affected family.
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DNA was extracted from whole blood using standard
techniques. Peripheral blood leukocytes obtained from
the patient were processed for DNA isolation using
standard methods. The entire coding region of VHL
gene was sequenced using direct Sanger sequencing
as described previously [6]. Large genomic rearrange-
ments were detected using MLPA analysis using the
SALSA MLPA kit P016 VHL assay (MRC Holland,
Amsterdam, The Netherlands). This assay includes 17
probes from distal chromosome 3p25 (from telomere
to centromere): one probe for CNTN6, two probes for
FANCD2, two probes for C3ORF10, four probes for VHLTable 1 VHL related and non-VHL related lesions detected









1 HbCb age 18, Hbs
age 19,Hbs age 31
Renal cysts
2 HbCb –age 54 RCC age 54 BrCa – age 46
BrCa – age 49
3 HbCb 65 NA
4 NA NA Pr – age 65
5 HbCb 69 NA
RCC renal cell carcinoma, BrCa – breast carcinoma, HbCb – heamangioblastoma
of cerebellum, Hbs – spinal haemangioblastoma, Pr – prostate cancer, NA- no
examination, no imaging studies.exon 1, three probes for VHL exon 2, two probes for VHL
exon 3, IRAK2 probe, GHR probe, and MLH1 probe. The
products of MLPA reactions were analyzed with automated
sequencer (model 373A, ABI, USA).
Results
In two patients with VHL disease, a large germline
deletion involving the exon 1 of the VHL gene, the
C3ORF10 gene and a fragment of the FANCD2 gene
was detected. The presence of the deletion was con-
firmed using MLPA in repeated analyses using DNA
samples isolated from two different blood samples for
each patient. In brief, in MLPA, the peak height was
significantly lower for the six probes (three probes for
VHL exon 1, two probes for C3ORF10 and 1 probe for
FANCD2 gene) indicating the presence of a heterozygous
deletion. Based of the localization of these six probes, we
estimate that the length of this deletion is approximately
50 kb (between 43 kb to 54 kb). The telomeric breakpoint
lies within the FANCD2 gene between exon 35 and exon
43 of the FANCD2 gene (a signal for the probe specific
for exon 43 of the FANCD2 gene was abnormal, and sig-
nal for the probe for exon 35 of the FANCD2 gene was
appropriate). The centromeric breakpoint is located in
intron 1 the VHL gene.
The clinical presentation of the VHL disease in this
family includes CNS heamangioblastoma seen in four
patients, kidney cancer diagnosed in one patient and no
retina heamangioblastoma or pheochromocytoma. Age of
diagnosis and localization of these typical VHL-associated
lesions are shown in Table 1.
Interestingly, one carrier of the deletion developed bi-
lateral breast cancer at age 46 and 49. First cancer was
diagnosed at the age of 46 in her right breast. The pa-
tient was treated by mastectomy with postoperative
chemotherapy (CMF). Histopathological examination
revealed invasive ductal breast carcinoma of 1.8 cm size.
The tumor was ER- negative, and PR-negative (HER2
was not analyzed). A metastasis in 1 axillary lymph node
was found. There was no evidence of distant metastases.
The tumor was classified as T1c pN1a M0, stage IIA;
grade G2. Three years later, at the age of 49, she was
diagnosed with cancer of her left breast. It was an inva-
sive ductal carcinoma of 2.0 cm size. The tumor was ER-
positive, PR-positive, and HER2-negative. There was
no evidence for lymph-node or distant metastases. The
tumor was classified as T1c pN 0 M0, stage IA, grade G2
and treated with mastectomy and tamoxifen. Ki67 ex-
pression was not tested. At present, 9 and 6 years after
treatment of the breast cancers there is no evidence of
breast cancer recurrence. However at age of 54, lesions
typical for VHL disease including cerebellar haemangio-
blastoma and renal cell carcinoma were diagnosed in the
patient.
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affected male family member at the age of 65 years
although his DNA sample was not available for MLPA
analysis.
Discussion
To our knowledge this is the first study to suggest an asso-
ciation between a large deletion involving the FANCD2
gene and bilateral breast cancer. FANCD2 is one of
eight genes known to cause the autosomal recessive
disorder Fanconi anaemia (FA), which is characterized
by spontaneous chromosomal instability, immunodefi-
ciency, and a predisposition to cancer [11-14]. FANCD2
plays an important role in the recombination DNA re-
pair pathways [15]. The activated FANCD2 protein
co-localises with other DNA repair proteins such as
BRCA1, BRCA2, ATM, NBS1 and RAD51 [16]. It has
been suggested that FANCD2 and BRCA1 interact di-
rectly in this process [11]. In response to ionising radi-
ation, FANCD2 is also phosphorylated by ATM, which
leads to the activation of an S-phase checkpoint of the
cell cycle [16]. Therefore, FANCD2 is good candidate for
breast cancer susceptibility gene.
It is interesting that biallelic mutations of BRCA2, the
major gene for hereditary breast cancer, were also shown
to cause Fanconi anemia. However, it has been reported
that FA gene mutations, other than in BRCA2, are un-
likely to be a frequent cause of highly penetrant breast
cancer predisposition. Analysis of the FA genes (FANCA,
B, C, D1, D2, E, F, G) in 88 non-BRCA1, non-BRCA2
breast cancer families failed to identify any highly pene-
trant mutations for breast cancer [17]. In another study,
399 women, from 356 non-BRCA1/2 breast cancer families
(some had more than one index case because multiple
women were affected at the same age), were screened for
FANCD2 mutations by DHPLC/sequencing and no patho-
genic mutations were identified [18].
In our study, breast cancers seen in carrier of a dele-
tion of FANCD2 gene were invasive, grade 2 ductal car-
cinomas. Both were tumors of ~2 cm in diameter. One
of these had lymph node metastases. One tumor was
ER- and PR-negative (HER2 status unknown) and the
other was ER- and PR-positive, but HER2-negative. This
may suggest that a mutation in FANCD2 predispose to
invasive breast cancer of ductal type, however further
studies are needed in this regard.
Given that both FANCD2 and BRCA2 mutations (in
homozygous state) cause the same chromosomal in-
stability syndrome called Fanconi anemia, it is likely that
breast cancers that arise in carriers of a mutation in
these genes may have similar clinical characteristics. In
this context it is important to mention that BRCA2-
associated breast cancers exhibit higher grade than spor-
adic tumors [19-22]. They are similar to sporadic cancerswith respect to ER receptor status [20,23-25]. However,
one study reported that BRCA2 associated tumors are
more likely to be ER-positive [22]. In addition, it has been
reported that BRCA2-related breast cancers are less likely
to over express HER2 receptor compared to sporadic
cancers [20,25]. Further studies are needed to investigate
whether FANCD2-related breast cancers are similar to
those seen BRCA2 mutation carriers.
In conclusion, our study suggests that a deletion of the
VHL and FANCD2 gene may be associated with coexist-
ence of VHL disease and hereditary breast cancer, but
further studies are needed in this regard.
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